Tech Company Financing Transactions
Mercy BioAnalytics Funding Round
Mercy BioAnalytics, based in Natick, secured $59 million from Novalis Biotech, Sozo Ventures and BrightEdge.
Transaction Overview
Company Name
Announced On
9/3/2025
Transaction Type
Venture Equity
Amount
$59,000,000
Round
Series B
Investors
Novalis Biotech (Lead Investor)
Sozo Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the commercialization of its blood-based ovarian cancer test portfolio, designed to detect ovarian cancer at earlier, more treatable stages across multiple indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
22 Strathmore Road 415
Natick, MA 01760
USA
Natick, MA 01760
USA
Phone
Undisclosed
Website
Email Address
Overview
Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dawn Mattoon
Browse more venture capital transactions:
Prev: 9/3/2025: Vali Cyber venture capital transaction
Next: 9/3/2025: XIFIN venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs